EP Patent

EP4621067A3 — Recombinant modified fibroblast growth factors and therapeutic uses thereof

Assigned to Trefoil Therapeutics Inc · Expires 2025-11-19 · 0y expired

What this patent protects

Described herein are modified fibroblast growth factor (FGF) polypeptides, pharmaceutical compositions and medicaments that include such modified FGF polypeptides, and methods of using such modified FGF polypeptides to treat or prevent conditions that benefit from administration …

USPTO Abstract

Described herein are modified fibroblast growth factor (FGF) polypeptides, pharmaceutical compositions and medicaments that include such modified FGF polypeptides, and methods of using such modified FGF polypeptides to treat or prevent conditions that benefit from administration of FGFs.

Drugs covered by this patent

Patent Metadata

Patent number
EP4621067A3
Jurisdiction
EP
Classification
—
Expires
2025-11-19
Drug substance claim
No
Drug product claim
No
Assignee
Trefoil Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.